Company Research Report: New Hope Molecular, LLC
Company Overview
- Name: New Hope Molecular, LLC
- Mission: At New Hope Molecular, we couple breakthrough scientific advances with personalized medicine to revolutionize the treatment of refractory psychiatric illness. Our mission is to identify underlying metabolic and genetic conditions contributing to treatment-refractory psychiatric illness, to advance characterization of mental health disorders, and to guide the most cutting-edge testing and treatment options for patients with treatment-refractory mental illness.
- Founded: The company was named after New Hope, Pennsylvania, which is significant to the founder, Lisa Pan, MD.
- Founder:
- Lisa Pan, M.D., F.A.P.A.: Dr. Pan has extensive experience in neurobiology research related to suicide attempts and treatment-refractory depression in adolescents and young adults. She is board certified in Psychiatry and Neurology with a subspecialty in Child and Adolescent Psychiatry.
- Key People:
- Lisa Pan, M.D., F.A.P.A.: Founder
- David Finegold, M.D.: Metabolic Lab Director
- Kelly Bayles, R.N.: Registered Nurse
- Bryan Overton, M.B.A.: Operations
- Patricia Dobosh, Ph.D.: Psychologist
- Angela Wagner, M.S.: Data Analyst
- Gary Kaplan, Esq.: Legal Counsel
- Headquarters: 750 Washington Rd., Suite 19, Pittsburgh, PA 15228
- Number of Employees: No information is available.
- Revenue: No information is available.
- Known For: The company is recognized for its approach in consultation for treatment-refractory depression and suicidal behavior, using comprehensive clinical metabolomic and genomic testing for psychiatric evaluation.
Products
- Primary Offerings:
- The company provides comprehensive metabolomic and genomic testing services to guide treatment for patients with treatment-refractory mental illness.
- Product Description:
- Comprehensive Psychiatric Evaluation: Includes detailed record review and individualized, data-driven analysis of metabolomic and genomic test results.
- Key Features:
- Full psychiatric evaluation.
- Comprehensive clinical metabolomic and genomic testing.
- Generation of a comprehensive report for doctors to guide patient care.
Recent Developments
- Recent Developments in the Company: No information is available.
- New Products Launched: No information is available.
- New Features Added: No information is available.
- Partnerships: No information is available.
In conclusion, New Hope Molecular aims to revolutionize the treatment of refractory psychiatric illnesses using advanced metabolomic and genomic methodologies. The company is moving forward under the expertise of a multidisciplinary team led by founder Dr. Lisa Pan.
